FTC Clears $338M Baxter-Prism Pharmaceuticals Deal

Law360, New York (May 6, 2011, 5:38 PM EDT) -- The Federal Trade Commission on Friday granted an early termination of its antitrust review of Baxter International Inc.'s purchase of Prism Pharmaceuticals Inc. in a deal worth up to $338 million for the private equity groups selling the specialty drugmaker.

The early termination means the agency has completed its antitrust review of the deal and decided not to take any enforcement action during the statutory waiting period.

Deerfield, Ill.-based Baxter said April 18 it would buy Prism Pharmaceuticals from Essex Woodlands Health Ventures Inc. and Paul...
To view the full article, register now.